COVID-19 Antibody Responses in Cystic Fibrosis
Completed
- Conditions
- Coronavirus diseaseCOVID-19 infection100474381002160510010613
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
Consenting people with cystic fibrosis of any age, genotype, transplant status
and disease severity will be eligible to participate in the study.
Exclusion Criteria
There are no specific exclusion criteria other than refusal to give informed
consent, or contraindication to blooddraw.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>• Proportion of people with cystic fibrosis with at least 1 seropositive result<br /><br>over the 2-year period.<br /><br>• Seroprevalence according to age group.<br /><br>• Seroprevalence according to geographical area.<br /><br>• Seroprevalence according to CF disease genotype and severity.<br /><br>• Change in seroprevalence over time.<br /><br>• Risk factors for infection in people with cystic fibrosis.</p><br>
- Secondary Outcome Measures
Name Time Method <p>• Incidence of symptomatic COVID-19 over the 2 year study period and symptom<br /><br>severity.<br /><br>• Proportion of seropositive people with cystic fibrosis with subsequent CF<br /><br>exacerbations compared to people with cystic fibrosis who are<br /><br>seronegative.<br /><br>• Morbidity and mortality in people with cystic fibrosis with at least 1<br /><br>seropositive result compared to people with cystic fibrosis who are<br /><br>seronegative.<br /><br>• Levels and duration of anti-SARS-CoV-2 antibodies in pwCF following natural<br /><br>infection and vaccination SARS-CoV-2.<br /><br>• Optional study objective: analysis of samples could include proteomic and<br /><br>genetic analysis and relating this to clinical outcome and antibody data<br /><br>collected as part of main study.</p><br>